System installation

RNS Number : 5782O

Polarean Imaging PLC

11 October 2021

 

11 October 2021

Polarean Imaging Plc

("Polarean" or the "Company")

System Installation

Polarean Imaging plc (AIM: POLX), the medical - imaging technology company, with an investigational drug - device combination product for magnetic resonance imaging (MRI), announces the installation of its 9820 Xenon Polariser system at BC Children's Hospital, Vancouver BC, a major paediatric research and teaching hospital.

The hyperpolarisation system order was previously announced in May 2021, with the system being used to support BC Children's Hospital's research into paediatric pulmonary disease.  

Richard Hullihen, Chief Executive Officer of Polarean commented: "We are pleased to complete the installation of an investigational 9820 Xenon Polariser system at BC Children's Hospital. We look forward to its use in research to expand the knowledge base in pulmonary disease areas."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

Polarean Imaging plc			www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer				Via Walbrook PR
Jonathan Allis, Non-Executive Chairman
Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)				[phone]
Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking)
Nick Adams / Fred Walsh (Corporate Broking)
Walbrook PR	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy		Mob: [phone]

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space. 

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (¹²⁹Xe) as an imaging agent to visualise ventilation. ¹²⁹Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual economic burden of pulmonary disease in the US is estimated to be over US$150 billion.

 

END

 

 

MSCEANEEFSXFFFA